(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Hostess Brands, Sleep Number Corporation, and Marathon.

The three biggest losers today are Verb Technology Company, Venus Concept , and ThermoGenesis Holdings.

Winners today

1. Hostess Brands (TWNKW) – 41.59%

Hostess Brands, Inc., a packaged food company, develops, manufactures, markets, sells, and distributes fresh sweet baked goods in the United States. It primarily offer a range of snack cakes, donuts, sweet rolls, breakfast pastries, snack pies, and related products. The company operates in two segments, Sweet Baked Goods and In-Store Bakery. The Sweet Baked Goods segment offers fresh and frozen sweet baked goods and bread products under the Hostess, Dolly Madison, Cloverhill, and Big Texas brands, as well as store branded products. The In-Store Bakery segment primarily provides Superior on Main branded eclairs, madeleines, brownies, and iced cookies in the bakery section of grocery and club stores. The company was formerly known as Gores Holdings, Inc. and changed its name to Hostess Brands, Inc. in November 2016. Hostess Brands, Inc. was founded in 1919 and is based in Lenexa, Kansas.

NASDAQ ended the session with Hostess Brands rising 41.59% to $3.20 on Monday, after five consecutive sessions in a row of losses. NASDAQ dropped 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

PE Ratio

Hostess Brands has a trailing twelve months price to earnings ratio of 5.15. Meaning, the purchaser of the share is investing $5.15 for every dollar of annual earnings.

Moving Average

Hostess Brands’s value is below its 50-day moving average of $3.36 and way higher than its 200-day moving average of $2.53.

More news about Hostess Brands.

2. Sleep Number Corporation (SNBR) – 33.03%

Sleep Number Corporation, together with its subsidiaries, offers sleep solutions and services in the United States. The company designs, manufactures, markets, retails, and services beds, pillows, sheets, and other bedding products under the Sleep Number name. It also provides adjustable bases under the FlextFit, and smart beds under the Sleep Number 360 brands. The company sells its products directly to consumers through retail, online, phone, and chat as well as through its e-commerce activities. As of January 2, 2022, it operated approximately 648 retail stores in 50 states. The company was formerly known as Select Comfort Corporation and changed its name to Sleep Number Corporation in November 2017. Sleep Number Corporation was founded in 1987 and is headquartered in Minneapolis, Minnesota.

NASDAQ ended the session with Sleep Number Corporation rising 33.03% to $14.70 on Monday, following the last session’s upward trend. NASDAQ slid 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Sleep Number Corporation has a trailing twelve months EPS of $-0.68.

Volume

Today’s last reported volume for Sleep Number Corporation is 2758180 which is 197.85% above its average volume of 926014.

More news about Sleep Number Corporation.

3. Marathon (MARA) – 23.31%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon rising 23.31% to $29.58 on Monday, following the last session’s downward trend. NASDAQ dropped 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-3.08.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.

Volatility

Marathon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.02%, a positive 1.70%, and a positive 6.71%.

Marathon’s highest amplitude of average volatility was 6.64% (last week), 6.72% (last month), and 6.71% (last quarter).

Yearly Top and Bottom Value

Marathon’s stock is valued at $29.58 at 16:32 EST, below its 52-week high of $31.30 and way higher than its 52-week low of $5.13.

Sales Growth

Marathon’s sales growth is 404.2% for the current quarter and 246.7% for the next.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 107.5% and 300%, respectively.

More news about Marathon.

4. SG Blocks (SGBX) – 21.44%

SG Blocks, Inc. designs and modifies code-engineered cargo shipping containers and purpose-built modules for commercial, industrial, and residential building construction in the United States. The company redesigns, repurposes, and convert heavy-gauge steel cargo shipping containers into SGBlocks, which are green building blocks for construction. It serves architects, landowners, builders, and developers. SG Blocks, Inc. was founded in 2007 and is headquartered in Jacksonville, Florida.

NASDAQ ended the session with SG Blocks rising 21.44% to $0.35 on Monday, following the last session’s upward trend. NASDAQ fell 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, SG Blocks has a trailing twelve months EPS of $-1.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -135.4%.

More news about SG Blocks.

5. Li Auto (LI) – 19.09%

Li Auto Inc., through its subsidiaries, designs, develops, manufactures, and sells new energy vehicles in the People's Republic of China. The company provides Li ONE and Li L series smart electric vehicles. It also offers sales and after sales management, and technology development and corporate management services, as well as purchases manufacturing equipment. The company offers its products through online and offline channels. The company was formerly known as Leading Ideal Inc. and changed its name to Li Auto Inc. in July 2020. Li Auto Inc. was founded in 2015 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Li Auto rising 19.09% to $41.44 on Monday, following the last session’s downward trend. NASDAQ slid 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Li Auto has a trailing twelve months EPS of $0.23.

PE Ratio

Li Auto has a trailing twelve months price to earnings ratio of 180.2. Meaning, the purchaser of the share is investing $180.2 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.89%.

Volume

Today’s last reported volume for Li Auto is 27328900 which is 308.47% above its average volume of 6690540.

More news about Li Auto.

6. Freshpet (FRPT) – 18.99%

Freshpet, Inc. manufactures and markets natural fresh meals and treats for dogs and cats in the United States, Canada, and Europe. The company sells its products under the Freshpet brand; and Dognation and Dog Joy labels through various classes of retail, including grocery, mass, club, pet specialty, and natural, as well as online. Freshpet, Inc. was incorporated in 2004 and is headquartered in Secaucus, New Jersey.

NASDAQ ended the session with Freshpet jumping 18.99% to $109.48 on Monday, after two consecutive sessions in a row of gains. NASDAQ fell 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Freshpet (frpt) beats Q4 earnings and revenue estimatesWhile Freshpet has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

Earnings Per Share

As for profitability, Freshpet has a trailing twelve months EPS of $-1.07.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.26%.

More news about Freshpet.

7. MicroStrategy (MSTR) – 17.2%

MicroStrategy Incorporated provides artificial intelligence-powered enterprise analytics software and services in the United States, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy ONE, which provides non-technical users with the ability to directly access novel and actionable insights for decision-making; and MicroStrategy Cloud for Government service, which offers always-on threat monitoring that meets the rigorous technical and regulatory needs of governments and financial institutions. The company also provides MicroStrategy Support that helps customers achieve their system availability and usage goals through highly responsive troubleshooting and assistance; MicroStrategy Consulting, which provides architecture and implementation services to help customers realize their desired results; and MicroStrategy Education that offers free and paid learning options. In addition, it engages in the development of bitcoin. The company offers its services through direct sales force and channel partners. It serves the U.S. government, state and local governments, and government agencies, as well as a range of industries, including retail, banking, technology, manufacturing, insurance, consulting, healthcare, telecommunications, and the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy jumping 17.2% to $805.65 on Monday, following the last session’s downward trend. NASDAQ fell 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $26.45.

PE Ratio

MicroStrategy has a trailing twelve months price to earnings ratio of 30.46. Meaning, the purchaser of the share is investing $30.46 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 48.17%.

More news about MicroStrategy.

8. Coinbase (COIN) – 17.13%

Coinbase Global, Inc. provides financial infrastructure and technology for the crypto economy in the United States and internationally. The company offers the primary financial account in the crypto economy for consumers; and a marketplace with a pool of liquidity for transacting in crypto assets for institutions. It also provides technology and services that enable developers to build crypto products and securely accept crypto assets as payment. The company was founded in 2012 and is based in Wilmington, Delaware.

NASDAQ ended the session with Coinbase rising 17.13% to $194.42 on Monday while NASDAQ fell 0.13% to $15,976.25.

Earnings Per Share

As for profitability, Coinbase has a trailing twelve months EPS of $0.37.

PE Ratio

Coinbase has a trailing twelve months price to earnings ratio of 525.46. Meaning, the purchaser of the share is investing $525.46 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.74%.

Volatility

Coinbase’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.84%, a positive 1.84%, and a positive 4.21%.

Coinbase’s highest amplitude of average volatility was 5.33% (last week), 5.21% (last month), and 4.21% (last quarter).

Sales Growth

Coinbase’s sales growth is negative 49% for the present quarter and negative 5.4% for the next.

More news about Coinbase.

9. Riot Blockchain (RIOT) – 15.82%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. The company operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. It also provides co-location services for institutional-scale bitcoin mining companies; critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners; operation of data centers; and maintenance/management of computing capacity. In addition, the company engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial, and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain jumping 15.82% to $17.20 on Monday, following the last session’s downward trend. NASDAQ slid 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-0.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.25%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Riot Blockchain’s stock is considered to be overbought (>=80).

Sales Growth

Riot Blockchain’s sales growth is 41.1% for the present quarter and 38.3% for the next.

More news about Riot Blockchain.

10. Stoke Therapeutics (STOK) – 11.65%

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

NASDAQ ended the session with Stoke Therapeutics rising 11.65% to $5.94 on Monday, following the last session’s upward trend. NASDAQ dropped 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Stoke Therapeutics has a trailing twelve months EPS of $-2.43.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -54.83%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is 3.1% and a drop 15.1% for the next.

Sales Growth

Stoke Therapeutics’s sales growth is negative 0.6% for the current quarter and negative 32.1% for the next.

Yearly Top and Bottom Value

Stoke Therapeutics’s stock is valued at $5.94 at 16:32 EST, way under its 52-week high of $14.00 and way above its 52-week low of $3.35.

More news about Stoke Therapeutics.

Losers Today

1. Verb Technology Company (VERBW) – -68.42%

Verb Technology Company, Inc. develops Software-as-a-Service applications platform. It offers verbLIVE, an interactive livestream eCommerce and shoppable video and webinar application; verbCRM, a white-labelled interactive video-based customer relationship management application; verbTEAMS, a self on-boarding version of verbCRM with built-in verbLIVE for small businesses and solo entrepreneurs; verbLEARN, an interactive video and gamified learning management system application; and verbMAIL, an interactive video mail solution integrated into Microsoft Outlook. The company provides non-digital services to enterprise clients, such as printing and fulfillment services. In addition, it offers subscription-based application services. The company serves large enterprises in the life sciences sector, professional sports franchises, and other business sectors. Verb Technology Company, Inc. was founded in 2012 and is based in Lehi, Utah.

NASDAQ ended the session with Verb Technology Company dropping 68.42% to $0.00 on Monday, after five successive sessions in a row of losses. NASDAQ slid 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Verb Technology Company has a trailing twelve months EPS of $-1.229.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -445.69%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 866.7%, now sitting on 9.47M for the twelve trailing months.

More news about Verb Technology Company.

2. Venus Concept (VERO) – -28.46%

Venus Concept Inc. operates as a medical aesthetic technology company worldwide. Its product portfolio includes aesthetic device platforms, including Venus Versa, a multi-treatment platform to address the aesthetic procedures without surgery or downtime; Venus Legacy, an advanced device that resolves challenging face and body aesthetic needs; Venus Velocity, a diode laser for hair removal; Venus Fiore, which addresses internal vaginal health restoration, labia skin tightening, and mons pubis reduction; Venus Viva, a customizable skin resurfacing device that allows operator control of ablation and coagulation for resolving the appearance of mild to severe skin damage for various skin types; Venus Freeze Plus, an anti-aging system for non-invasive skin tightening; and Venus Bliss, a solution for the fat reduction category. The company also offers NeoGraft, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process; and ARTAS and ARTAS iX robotic hair restoration systems, which harvest follicular units directly from the scalp and create recipient implant sites using proprietary algorithms. Venus Concept Inc. is headquartered in Toronto, Canada.

NASDAQ ended the session with Venus Concept dropping 28.46% to $0.93 on Monday, following the last session’s downward trend. NASDAQ fell 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Venus Concept has a trailing twelve months EPS of $-6.87.

Moving Average

Venus Concept ‘s value is way below its 50-day moving average of $1.21 and way under its 200-day moving average of $1.84.

Revenue Growth

Year-on-year quarterly revenue growth declined by 18.2%, now sitting on 82.51M for the twelve trailing months.

More news about Venus Concept .

3. ThermoGenesis Holdings (THMO) – -21.7%

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

NASDAQ ended the session with ThermoGenesis Holdings falling 21.7% to $0.83 on Monday while NASDAQ slid 0.13% to $15,976.25.

Earnings Per Share

As for profitability, ThermoGenesis Holdings has a trailing twelve months EPS of $-7.22.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -395.62%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 3.7%, now sitting on 9.71M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ThermoGenesis Holdings’s EBITDA is -7.65.

More news about ThermoGenesis Holdings.

4. E.W. Scripps Company (SSP) – -19.48%

The E.W. Scripps Company, together with its subsidiaries, operates as a media enterprise through a portfolio of local and national media brands. The company operates through Local Media, Scripps Network, and Other segments. The Local Media segment operates broadcast television stations, which produce news, information, and entertainment content, as well as its related digital operations. This segment also runs network, syndicated, and original programming. The Scripps Network segment comprises of national television networks. The Network operates through over-the-air broadcast, cable/satellite, connected TV, and digital distribution. In addition, the company provides content and services through the internet, smartphones, and tablets. Further, the company provides Newsy, a national news network, which provides politics, entertainment, science, and technology news; and Scripps National Spelling Bee, an investigative reporting newsroom in Washington, D.C. Additionally, the company offers ION, a national broadcast television network that delivers popular crime and justice procedural programming through over-the-air broadcast and pay TV platforms. It serves audiences and businesses. The E.W. Scripps Company operates through a network of 61 television stations. The company was founded in 1878 and is headquartered in Cincinnati, Ohio.

NASDAQ ended the session with E.W. Scripps Company dropping 19.48% to $4.34 on Monday, after five sequential sessions in a row of losses. NASDAQ slid 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, E.W. Scripps Company has a trailing twelve months EPS of $-11.84.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -57.67%.

Sales Growth

E.W. Scripps Company’s sales growth is negative 11.6% for the ongoing quarter and 6.9% for the next.

Yearly Top and Bottom Value

E.W. Scripps Company’s stock is valued at $4.34 at 16:32 EST, way below its 52-week high of $13.07 and higher than its 52-week low of $4.26.

Moving Average

E.W. Scripps Company’s worth is way under its 50-day moving average of $7.38 and way under its 200-day moving average of $7.60.

Earnings Before Interest, Taxes, Depreciation, and Amortization

E.W. Scripps Company’s EBITDA is 41.84.

More news about E.W. Scripps Company.

5. TransMedics Group (TMDX) – -9.61%

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

NASDAQ ended the session with TransMedics Group falling 9.61% to $75.15 on Monday while NASDAQ slid 0.13% to $15,976.25.

Earnings Per Share

As for profitability, TransMedics Group has a trailing twelve months EPS of $-1.09.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.77%.

Volume

Today’s last reported volume for TransMedics Group is 866498 which is 90.68% above its average volume of 454418.

Earnings Before Interest, Taxes, Depreciation, and Amortization

TransMedics Group’s EBITDA is -80.17.

Sales Growth

TransMedics Group’s sales growth is 118.4% for the current quarter and 79.7% for the next.

More news about TransMedics Group.

6. Renalytix AI plc (RNLX) – -9.49%

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

NASDAQ ended the session with Renalytix AI plc falling 9.49% to $0.67 on Monday, following the last session’s downward trend. NASDAQ dropped 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Renalytix AI plc has a trailing twelve months EPS of $-0.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -651.4%.

Sales Growth

Renalytix AI plc’s sales growth is 51.9% for the ongoing quarter and 276.4% for the next.

Revenue Growth

Year-on-year quarterly revenue growth declined by 40.5%, now sitting on 2.41M for the twelve trailing months.

Moving Average

Renalytix AI plc’s value is way above its 50-day moving average of $0.46 and way below its 200-day moving average of $1.62.

More news about Renalytix AI plc.

7. Verb Technology Company (VERB) – -9.2%

Verb Technology Company, Inc. develops Software-as-a-Service applications platform. It offers verb Customer Relationship Management (CRM) application; verbLEARN, a Learning Management System application that incorporates clickable in-video technology featured in its verbCRM application; and verbLIVE, a Live Broadcast Video Webinar application. The company also provides non-digital services to enterprise clients, such as printing and fulfillment services; subscription-based application services; design and printing services to create corporate starter kits for their marketing needs; print on demand and fulfilment services of various custom products for marketing purposes; and shipping services. In addition, it provides its products for large professional associations, educational institutions, auto sales, auto leasing, insurance, real estate, home security, not-for-profits, as well as clients in the health care industry, burgeoning CBD industry, and other business sectors. The company has operations in the United States and Japan. The company was formerly known as nFüsz, Inc. and changed its name to Verb Technology Company, Inc. in February 2019. Verb Technology Company, Inc. was founded in 2014 and is headquartered in Newport Beach, California.

NASDAQ ended the session with Verb Technology Company falling 9.2% to $0.15 on Monday, following the last session’s upward trend. NASDAQ fell 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Verb Technology Company has a trailing twelve months EPS of $-12.04.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -445.69%.

Sales Growth

Verb Technology Company’s sales growth for the next quarter is negative 95.5%.

More news about Verb Technology Company.

8. Insulet (PODD) – -8.32%

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

NASDAQ ended the session with Insulet sliding 8.32% to $168.88 on Monday, following the last session’s downward trend. NASDAQ dropped 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Insulet has a trailing twelve months EPS of $2.95.

PE Ratio

Insulet has a trailing twelve months price to earnings ratio of 57.25. Meaning, the purchaser of the share is investing $57.25 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.13%.

More news about Insulet.

9. Tantech Holdings Ltd. (TANH) – -7.69%

Tantech Holdings Ltd, together with its subsidiaries, develops and manufactures bamboo-based charcoal products for industrial energy, household cooking, heating, purification, agricultural, and cleaning applications in the People's Republic of China and internationally. The company operates in three segments: Consumer Products, Trading, and Electric Vehicle. It provides pressed and formed charcoal briquettes for use in grills, incense burners, and other applications under the Algold brand. The company also offers Charcoal Doctor branded products, such as air purifiers and humidifiers, automotive accessories for air purification, underfloor humidity control products, pillows and mattresses, wardrobe deodorizers, mouse pads and wrist mats, refrigerator deodorants, charcoal toilet cleaner disks, liquid charcoal cleaners, shoe insoles, and decorative charcoal gifts. In addition, it provides bamboo vinegar, a liquid byproduct for use in disinfectants, detergents, lotions, specialized soaps, toilet cleaners, and fertilizers, as well as in various agricultural applications; and trades in charcoal products. Further, the company develops and sells electric buses, electric logistics cars, and specialty electric vehicles, such as brushless cleaning cars, electric cleaning cars, special emergency vehicles, and funeral cars; and solar cells, lithium-ion batteries, auto parts, and electric control systems. It is also involved in the supply chain business. Tantech Holdings Ltd was founded in 2001 and is headquartered in Lishui, the People's Republic of China.

NASDAQ ended the session with Tantech Holdings Ltd. dropping 7.69% to $0.72 on Monday, after two sequential sessions in a row of losses. NASDAQ fell 0.13% to $15,976.25, following the last session’s downward trend on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Tantech Holdings Ltd. has a trailing twelve months EPS of $1.37.

PE Ratio

Tantech Holdings Ltd. has a trailing twelve months price to earnings ratio of 0.53. Meaning, the purchaser of the share is investing $0.53 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.2%.

Volume

Today’s last reported volume for Tantech Holdings Ltd. is 163748 which is 71.97% below its average volume of 584321.

Revenue Growth

Year-on-year quarterly revenue growth declined by 26.8%, now sitting on 46.26M for the twelve trailing months.

More news about Tantech Holdings Ltd..

10. TRACON Pharmaceuticals (TCON) – -7.62%

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

NASDAQ ended the session with TRACON Pharmaceuticals falling 7.62% to $0.17 on Monday while NASDAQ slid 0.13% to $15,976.25.

Earnings Per Share

As for profitability, TRACON Pharmaceuticals has a trailing twelve months EPS of $-0.44.

Yearly Top and Bottom Value

TRACON Pharmaceuticals’s stock is valued at $0.17 at 16:32 EST, way below its 52-week high of $2.19 and way higher than its 52-week low of $0.13.

Volume

Today’s last reported volume for TRACON Pharmaceuticals is 1356080 which is 26.51% below its average volume of 1845420.

Earnings Before Interest, Taxes, Depreciation, and Amortization

TRACON Pharmaceuticals’s EBITDA is -0.17.

Moving Average

TRACON Pharmaceuticals’s worth is under its 50-day moving average of $0.18 and way under its 200-day moving average of $0.28.

More news about TRACON Pharmaceuticals.

Stay up to date with our winners and losers daily report